NEOPLASMS OF THE PROSTATE GLAND CHAPTER 23
Andriole GL et al: Effect of dutasteride on the risk of prostate cancer.
N Engl J Med 2010;362(13):1192–1202.
Carroll PR et al: Serum prostate-specific antigen for the early detec-
tion of prostate cancer: Always, never, or only sometimes? J Clin
Oncol 2011;29:345.
Crawford ED et al: Comorbidity and mortality results from a ran-
domized prostate cancer screening trial. Clin Oncol 2011;29(4):
355–361.
Draisma G et al: Lead time and overdiagnosis in prostate-specific
antigen screening: Importance of methods and context. J Natl
Cancer Inst 2009;101:374–383.
Greene KL et al: Prostate specific antigen best practice statement:
2009 update. J Urol 2009;182(5):2232–2241.
Harris RE et al: Aspirin, ibuprofen, and other non-steroidal anti-
inflammatory drugs in cancer prevention: A critical review of
non-selective COX-2 blockade (review). Oncol Rep 2005;13(4):
559–583.
Hugosson J et al: Mortality results from the Göteborg randomised
population-based prostate-cancer screening trial. Lancet Oncol
2010;11(8):725–732.
Jones JS et al: Saturation biopsy with periprostatic block can be per-
formed in the office. J Urol 2002;168:2108.
Kramer BS et al: Use of 5-α-reductase inhibitors for prostate cancer
chemoprevention: American Society of Clinical Oncology/Ameri-
can Urological Association 2008 clinical practice guideline. J Clin
Oncol 2009;27:1502–1516.
Lippman SM et al: Effect of selenium and vitamin E on risk of pros-
tate cancer and other cancers: the Selenium and Vitamin E Cancer
Prevention Trial (SELECT). JAMA 2009;301:39.
Nelson WG : Agents in development for prostate cancer prevention.
Expert Opin Investig Drugs 2004;13(12):1541–1554.
Parnes HL et al: Prevention of hormone-related cancers: Prostate
cancer. J Clin Oncol 2005;23(2):368–377.
Schröder FH et al: Screening and prostate-cancer mortality in a ran-
domized European study. N Engl J Med 2009;360(13):1320–1328.
Theoret MR et al: The Risks and Benefits of 5α-Reductase Inhibitors
for Prostate-Cancer Prevention. N Engl J Med 2011;365(2):97–99.
Thompson IM et al: The influence of finasteride on the development
of prostate cancer. N Engl J Med 2003;349(3):215–224.
Thompson IM et al: Prevalence of prostate cancer among men with
a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl
J Med 2004;350(22):2239–2246.
Unger JM et al: Estimated impact of the Prostate Cancer Prevention
Trial on population mortality. Cancer 2005;103(7):1375–1380.
U.S. Preventive Services Task Force: Screening for prostate cancer.
Ann Intern Med 2008;149:185–191.
Vickers AJ et al: Prostate specific antigen concentration at age 60 and
death or metastasis from prostate cancer: Case-control study. BMJ
2010;341:c4521.
Serum Tumor Markers
Banez LL et al: Obesity-related plasma hemodilution and PSA con-
centration among men with prostate cancer. JAMA 2007;298:
2275.
Catalona WJ et al: Use of the percentage of free prostate-specific anti-
gen to enhance differentiation of prostate cancer from benign
prostatic disease: A prospective multicenter clinical trial. JAMA
1998;279(19):1542–1547.

375
Catalona WJ et al: Serum pro-prostate specific antigen preferentially
detects aggressive prostate cancers in men with 2 to 4 ng/ml pros-
tate specific antigen. J Urol 2004;171(6, Pt 1):2239–2244.
Catalona WJ et al: A multicenter study of [-2]pro-prostate specific
antigen combined with prostate specific antigen and free prostate
specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/
ml prostate specific antigen range. J Urol 2011;185:1650.
Cooney KA et al: Age-specific distribution of serum prostate-specific
antigen in a community-based study of African-American men.
Urology 2001;57(1):91–96.
D’Amico AV et al: Preoperative PSA velocity and the risk of death
from prostate cancer after radical prostatectomy. N Engl J Med
2004;351(2):125–135.
D’Amico AV et al: Prostate specific antigen doubling time as a sur-
rogate end point for prostate cancer specific mortality following
radical prostatectomy or radiation therapy. J Urol 2004;172(5, Pt
2):S42–S46; discussion S46–S47.
Djavan B et al: Complexed prostate-specific antigen, complexed
prostate-specific antigen density of total and transition zone,
complexed/total prostate-specific antigen ratio, free-to-total
prostate-specific antigen ratio, density of total and transition zone
prostate-specific antigen: Results of the prospective multicenter
European trial. Urology 2002;60(4, Suppl 1):4–9.
Eggener SE et al: Predictors of subsequent prostate cancer in men
with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially
negative biopsy. J Urol 2005;174(2):500–504.
Etzioni R et al: Prostate-specific antigen and free prostate-specific
antigen in the early detection of prostate cancer: Do combination
tests improve detection? Cancer Epidemiol Biomarkers Prev
2004;13(10):1640–1645.
Groskopf J et al: APTIMA PCA3 molecular urine test: Development
of a method to aid in the diagnosis of prostate cancer. Clin Chem
2006;52:1089.
Haese A et al: Clinical utility of the PCA3 urine assay in European
men scheduled for repeat biopsy. Eur Urol 2008;54:1081.
Hessels D et al: Detection of TMPRSS2-ERG fusion transcripts and
prostate cancer antigen 3 in urinary sediments may improve diag-
nosis of prostate cancer. Clin Cancer Res 2007;13:5103.
Lein M et al: A multicenter clinical trial on the use of (-5, -7) pro
prostate specific antigen. J Urol 2005;174(6):2150–2153.
Mikolajczyk SD et al: Proenzyme forms of prostate-specific antigen
in serum improve the detection of prostate cancer. Clin Chem
2004;50(6):1017–1025.
Oesterling JE et al: Serum prostate-specific antigen in a community-
based population of healthy men. Establishment of age-specific
reference ranges. JAMA 1993;270(7):860–864.
Pan CC et al: The association between presentation PSA and race in
two sequential time periods in prostate cancer patients seen at a
university hospital and its community affiliates. Int J Radiat Oncol
Biol Phys 2003;57(5):1292–1296.
Patel DA et al: Preoperative PSA velocity is an independent prognostic
factor for relapse after radical prostatectomy. J Clin Oncol 2005;
23(25):6157–6162.
Paul B et al: Detection of prostate cancer with a blood-based assay
for early prostate cancer antigen. Cancer Res 2005;65(10):
4097–5100.
Roddam AW et al: Use of prostate-specific antigen (PSA) isoforms
for the detection of prostate cancer in men with a PSA level of
2–10 ng/ml: Systematic review and meta-analysis. Eur Urol 2005;
48(3):386–399; discussion 398–399.
 376
SMITH & TANAGHO’S GENERAL UROLOGY
Tewari A et al: Racial differences in serum prostate-specific antigen
(PSA) doubling time, histopathological variables and long-term
PSA recurrence between African-American and white American
men undergoing radical prostatectomy for clinically localized
prostate cancer. BJU Int 2005;96(1):29–33.
Thompson IM et al: Operating characteristics of prostate-specific
antigen in men with an initial PSA level of 3.0 ng/ml or lower.
JAMA 2005;294(1):66–70.
Vickers AJ et al: Reducing unnecessary biopsy during prostate cancer
screening using a four-kallikrein panel: An independent replication.
J Clin Oncol 2010;28:2493.
Vickers AJ et al: An empirical evaluation of guidelines on prostate-
specific antigen velocity in prostate cancer detection. J Natl Cancer
Inst 2011;103:462.
Staging and Risk Assessment
Cooperberg MR et al: The University of California, San Francisco
Cancer of the Prostate Risk Assessment score: A straightforward
and reliable preoperative predictor of disease recurrence after
radical prostatectomy. J Urol 2005;173(6):1938–1942.
Cooperberg MR . Prostate cancer risk assessment: choosing the
sharpest tool in the shed. Cancer 2008;113(11):3062–3066.
Cooperberg MR et al: Risk assessment for prostate cancer metastasis
and mortality at the time of diagnosis. J Natl Cancer Inst 2009;
101(12):878–887.
D’Amico AV et al: Biochemical outcomes after radical prostatectomy,
external beam radiation therapy, or interstitial radiation therapy
for clinically localized prostate cancer. JAMA 1998;280:969.
Lughezzani G et al: Head-to-head comparison of the three most
commonly used preoperative models for prediction of biochemi-
cal recurrence after radical prostatectomy. Eur Urol 2010;57:562.
Makarov DV et al: Updated nomogram to predict pathologic stage of
prostate cancer given prostate-specific antigen level, clinical stage,
and biopsy Gleason score (Partin tables) based on cases from 2000
to 2005. Urology 2007;69:1095.
Porten SP et al: The independent value of tumour volume in a con-
temporary cohort of men treated with radical prostatectomy for
clinically localized disease. BJU Int 105:472, 2010.
Reese AC et al: Inaccuracies in assignment of clinical stage for local-
ized prostate cancer. Cancer 117:283, 2011.
Shariat SF et al: An updated catalog of prostate cancer predictive
tools. Cancer 2008;113:3075–3099.
Zhou P et al: Predictors of prostate cancer-specific mortality after
radical prostatectomy or radiation therapy. J Clin Oncol
2005;23(28):6992–6998.
Imaging
Afnan J et al: Update on prostate imaging. Urol Clin North Am
2010;37:23.
Bander NH : Technology insight: monoclonal antibody imaging of
prostate cancer. Nat Clin Pract Urol 2006;3:216.
Halpern EJ et al: Prostate: High-frequency Doppler US imaging for
cancer detection. Radiology 2002;225(1):71–77.
Harisinghani MG et al: Noninvasive detection of clinically occult
lymph-node metastases in prostate cancer. N Engl J Med
2003;348(25):2491–2499.
Kizu H et al: Fusion of SPECT and multidetector CT images for
accurate localization of pelvic sentinel lymph nodes in prostate
cancer patients. J Nucl Med Technol 2005;33(2):78–82.
Mahdavi SS et al: Evaluation of visualization of the prostate gland in
vibro-elastography images. Med Image Anal 2011;15(4):589–600.
Palvolgi R et al: Bone scan overuse in staging of prostate cancer: An
analysis of a Veterans Affairs Cohort. Urology 2011;77:1330–1337.
Ponsky LE et al: Evaluation of preoperative ProstaScint scans in the
prediction of nodal disease. Prostate Cancer Prostatic Dis
2002;5(2):132–135.
Sanna V et al: Development of polymeric microbubbles targeted to
prostate-specific membrane antigen as prototype of novel ultra-
sound contrast agents. Mol Pharm 2011;8(3):748–757.
Thomas CT et al: Indium-111-capromab pendetide radioimmunos-
cintigraphy and prognosis for durable biochemical response to
salvage radiation therapy in men after failed prostatectomy. J Clin
Oncol 2003;21(9):1715–1721.
Verma S et al: Prostate MRI and 3D MR spectroscopy: how we do it.
Am J Roentgenol 2010;194(6):1414–1426.
Prostate Biopsy
Epstein JI et al: Utility of saturation biopsy to predict insignificant
cancer at radical prostatectomy. Urology 2005;66(2):356–360.
Karakiewicz PI et al: Development and validation of a nomogram
predicting the outcome of prostate biopsy based on patient age,
digital rectal examination and serum prostate specific antigen.
J Urol 2005;173(6):1930–1934.
Lange D et al: Bacterial sepsis after prostate biopsy–A new perspec-
tive. Urology 2009;74:1200.
Obek C et al: Comparison of 3 different methods of anesthesia
before transrectal prostate biopsy: A prospective randomized trial.
J Urol 2004;172(2):502–505.
Pelzer AE et al: Are transition zone biopsies still necessary to improve
prostate cancer detection? Results from the Tyrol screening project.
Eur Urol 2005;48(6):916–921; discussion 921.
Pinkstaff DM et al: Systematic transperineal ultrasound-guided tem-
plate biopsy of the prostate: Three-year experience. Urology 2005;
65(4):735–739.
Presti JC Jr et al: The optimal systematic prostate biopsy scheme
should include 8 rather than 6 biopsies: Results of a prospective
clinical trial. J Urol 2000;163(1):163–166; discussion 166–167.
Rabets JC et al: Prostate cancer detection with office based saturation
biopsy in a repeat biopsy population. J Urol 2004;172(1):94–97.
Remzi M et al: The Vienna nomogram: Validation of a novel biopsy
strategy defining the optimal number of cores based on patient
age and total prostate volume. J Urol 2005;174(4, Pt 1):1256–1260;
discussion 1260–1261; author reply 1261.
Sheikh M et al: Patients’ tolerance and early complications of tran-
srectal sonographically guided prostate biopsy: Prospective study
of 300 patients. J Clin Ultrasound 2005;33(9):452–456.
Radical Prostatectomy
Allaf ME et al: Anatomical extent of lymph node dissection: Impact
on men with clinically localized prostate cancer. J Urol 2004;172(5,
Pt 1):1840–1844.
Bader P et al: Disease progression and survival of patients with posi-
tive lymph nodes after radical prostatectomy. Is there a chance of
cure? J Urol 2003;169(3):849–854.
Barocas DA et al: Robotic assisted laparoscopic prostatectomy versus
radical retropubic prostatectomy for clinically localized prostate
cancer: Comparison of short-term biochemical recurrence-free
survival. J Urol 2010;183:990.
 NEOPLASMS OF THE PROSTATE GLAND
Bhatta-Dhar N et al: No difference in six-year biochemical failure
rates with or without pelvic lymph node dissection during radical
prostatectomy in low-risk patients with localized prostate cancer.
Urology 2004;63(3):528–531.
Bill-Axelson A et al: Radical prostatectomy versus watchful waiting in
early prostate cancer. N Engl J Med 2011;364:1708–1717.
Bolla M et al: Postoperative radiotherapy after radical prostatectomy:
A randomised controlled trial (EORTC trial 22911). Lancet
2005;366(9485):572–578.
Cooperberg MR et al: Comparative risk-adjusted mortality out-
comes after primary surgery, radiotherapy, or androgen-depriva-
tion therapy for localized prostate cancer. Cancer 2010;116:5226.
Cooperberg MR et al: The CAPRA-S score: A straightforward tool for
improved prediction of outcomes after radical prostatectomy.
Cancer 2011;117(22):5039–5046.
Dotan ZA et al: Pattern of prostate-specific antigen (PSA) failure dic-
tates the probability of a positive bone scan in patients with an
increasing PSA after radical prostatectomy. J Clin Oncol
2005;23(9):1962–1968.
Ficarra V et al: Retropubic, laparoscopic, and robot-assisted radical
prostatectomy: A systematic review and cumulative analysis of
comparative studies. Eur Urol 2009 55:1037–1063.
Guillonneau B et al: Laparoscopic radical prostatectomy: Oncologi-
cal evaluation after 1,000 cases a Montsouris Institute. J Urol
2003;169(4):1261–1266.
Karakiewicz PI et al: Prognostic impact of positive surgical margins
in surgically treated prostate cancer: Multi-institutional assess-
ment of 5831 patients. Urology 2005;66(6):1245–1250.
Lunacek A et al: Anatomical radical retropubic prostatectomy: “Cur-
tain dissection” of the neurovascular bundle. BJU Int
2005;95(9):1226–1231.
Messing EM et al: Immediate versus deferred androgen deprivation
treatment in patients with node-positive prostate cancer after
radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol
2006;7:472–479.
Patel DA et al: Preoperative PSA velocity is an independent prognos-
tic factor for relapse after radical prostatectomy. J Clin Oncol
2005;23(25):6157–6162.
Rogers CG et al: Natural history of disease progression in patients
who fail to achieve an undetectable prostate-specific antigen level
after undergoing radical prostatectomy. Cancer 2004;101(11):
2549–2556.
Stephenson AJ et al: Postoperative nomogram predicting the 10-year
probability of prostate cancer recurrence after radical prostatec-
tomy. J Clin Oncol 2005;23(28):7005–7012.
Stephenson AJ et al: Predicting the outcome of salvage radiation
therapy for recurrent prostate cancer after radical prostatectomy.
J Clin Oncol 2007;25:2035.
Stephenson AJ et al: Prostate cancer–specific mortality after radical
prostatectomy for patients treated in the prostate-specific antigen
era. J Clin Oncol 2009;27:4300.
Swindle P et al: Do margins matter? The prognostic significance of
positive surgical margins in radical prostatectomy specimens.
J Urol 2005;174(3):903–907.
Thompson IM et al: Adjuvant radiotherapy for pathological
T3N0M0 prostate cancer significantly reduces risk of metastases
and improves survival: Long-term followup of a randomized clin-
ical trial. J Urol 2009;181:956.
Zelefsky MJ et al: Metastasis after radical prostatectomy or external
beam radiotherapy for patients with clinically localized prostate
CHAPTER 23
377
cancer: A comparison of clinical cohorts Adjusted for case mix.
J Clin Oncol 2010;28:1508.
Radiation
Ashman JB et al: Whole pelvic radiotherapy for prostate cancer using
3D conformal and intensity-modulated radiotherapy. Int
J Radiat Oncol Biol Phys 2005;63(3):765–771.
Ataman F et al: Late toxicity following conventional radiotherapy for
prostate cancer: Analysis of the EORTC trial 22863. Eur J Cancer
2004;40(11):1674–1681.
Bhojani N et al: The rate of secondary malignancies after radical
prostatectomy versus external beam radiation therapy for local-
ized prostate cancer: A population-based study on 17,845 patients.
Int J Radiat Oncol Biol Phys 2010;76(2):342–348.
Bolla M et al: Long-term results with immediate androgen suppres-
sion and external irradiation in patients with locally advanced
prostate cancer (an EORTC study): A phase III randomised trial.
Lancet 2002;360(9327):103–106.
Buyyounouski MK et al: Defining biochemical failure after radio-
therapy with and without androgen deprivation for prostate can-
cer. Int J Radiat Oncol Biol Phys 2005;63(5):1455–1462.
Ciezki JP et al: A retrospective comparison of androgen deprivation
(AD) vs. no AD among low-risk and intermediate-risk prostate
cancer patients treated with brachytherapy, external beam radio-
therapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys
2004;60(5):1347–1350.
D’Amico AV et al: 6-month androgen suppression plus radiation
therapy vs radiation therapy alone for patients with clinically
localized prostate cancer: A randomized controlled trial. JAMA
2004;292(7):821–827.
Hanks GE et al: Phase III trial of long-term adjuvant androgen depri-
vation after neoadjuvant hormonal cytoreduction and radiother-
apy in locally advanced carcinoma of the prostate: The Radiation
Therapy Oncology Group Protocol 92–02. J Clin Oncol
2003;21(21):3972–3978.
Horwitz EM et al: Ten-year follow-up of radiation therapy oncology
group protocol 92–02: A phase III trial of the duration of elective
androgen deprivation in locally advanced prostate cancer. J Clin
Oncol 2008;26:2497–2504.
Konski A et al: Is proton beam therapy cost effective in the treatment
of adenocarcinoma of the prostate. J Clin Oncol 2007;25:3603.
Lawton CA et al: Androgen suppression plus radiation versus radia-
tion alone for patients with stage D1/pathologic node-positive
adenocarcinoma of the prostate: Updated results based on national
prospective randomized trial Radiation Therapy Oncology Group
85–31. J Clin Oncol 2005;23(4):800–807.
Lee CT et al: Comparison of treatment volumes and techniques in
prostate cancer radiation therapy. Am J Clin Oncol 2005;28(6):
618–625.
Merrick GS et al: Impact of supplemental external beam radiother-
apy and/or androgen deprivation therapy on biochemical out-
come after permanent prostate brachytherapy. Int J Radiat Oncol
Biol Phys 2005;61(1):32–43.
Potters L et al: Potency after permanent prostate brachytherapy for
localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;
50:1235.
Roach M III et al: Phase III trial comparing whole-pelvic versus pros-
tate-only radiotherapy and neoadjuvant versus adjuvant com-
bined androgen suppression: Radiation Therapy Oncology Group
9413. J Clin Oncol 2003;21(10):1904–1911.
 378
SMITH & TANAGHO’S GENERAL UROLOGY
Vargas CE et al: Lack of benefit of pelvic radiation in prostate cancer
patients with a high risk of positive pelvic lymph nodes treated
with high-dose radiation. Int J Radiat Oncol Biol Phys 2005;
63(5):1474–1482.
Zietman AL et al: Comparison of conventional-dose vs high-dose
conformal radiation therapy in clinically localized adenocarci-
noma of the prostate: A randomized controlled trial. JAMA
2005;294(10):1233–1239.
Zietman AL et al: PSA bounces after neoadjuvant androgen depriva-
tion and external beam radiation: Impact on definitions of failure.
Int J Radiat Oncol Biol Phys 2005;62(3):714–718.
Active Surveillance
Albertsen PC et al: Impact of comorbidity on survival among men
with localized prostate cancer. J Clin Oncol 2011;29:1335.
Cooperberg MR et al: Outcomes of active surveillance for men with
intermediate-risk prostate cancer. J Clin Oncol 2011a;29:228–234.
Cooperberg MR et al: Active surveillance for prostate cancer: Prog-
ress and promise. J Clin Oncol 2011b;29(27):3669–3676. Review.
Harlan SR et al: Time trends and characteristics of men choosing
watchful waiting for initial treatment of localized prostate cancer:
Results from CapSure. J Urol 2003;170(5):1804–1807.
Hayes JH et al: Active surveillance compared with initial treatment
for men with low-risk prostate cancer: A decision analysis. JAMA
2010;304(21):2373–2380.
Kattan MW et al: Counseling men with prostate cancer: a nomogram
for predicting the presence of small, moderately differentiated,
confined tumors. J Urol 2003;170(5):1792–1797.
Klotz L et al: Clinical results of long-term follow-up of a large, active
surveillance cohort with localized prostate cancer. J Clin Oncol
2009;28:126–131.
Lu-Yao GL et al: Outcomes of localized prostate cancer following
conservative management. JAMA 2009;302(11):1202–1209.
Porten S et al: Changes in prostate cancer grade on serial biopsy in
men undergoing active surveillance. J Clin Oncol 2011;29:795–800.
Ross AE et al: Prostate-specific antigen kinetics during follow-up are
an unreliable trigger for intervention in a prostate cancer surveil-
lance program. J Clin Oncol 2010;28:2810.
Tosoian JJ et al: Active surveillance program for prostate cancer: An
update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185.
Cryotherapy and HIFU
Colombel M , Gelet A : Principles and results of high-intensity
focused ultrasound for localized prostate cancer. Prostate Cancer
Prostatic Dis 2004;7(4):289–294.
Donnelly BJ et al: Role of transrectal ultrasound guided salvage cryo-
surgery for recurrent prostate carcinoma after radiotherapy. Pros-
tate Cancer Prostatic Dis 2005;8(3):235–242.
Onik G : The male lumpectomy: Rationale for a cancer targeted
approach for prostate cryoablation. A review. Technol Cancer Res
Treat 2004;3(4):365–370.
Shinohara K : Prostate cancer: Cryotherapy. Urol Clin North Am
2003;30(4):725–736, viii.
Quality of Life
Miller DC et al: Long-term outcomes among localized prostate can-
cer survivors: Health-related quality-of-life changes after radical
prostatectomy, external radiation, and brachytherapy. J Clin
Oncol 2005;23(12):2772–2780.
Pardo Y et al: Quality-of-life impact of primary treatments for local-
ized prostate cancer in patients without hormonal treatment.
J Clin Oncol 2010;28:4687.
Sanda MG et al: Quality of life and satisfaction with outcome among
prostate-cancer survivors. N Engl J Med 2008;358:1250–1261.
Sonn GA et al: Differing perceptions of quality of life in patients with
prostate cancer and their doctors. J Urol 2009;182:2296.
Speight JL et al: Longitudinal assessment of changes in sexual func-
tion and bother in patients treated with external beam radiother-
apy or brachytherapy, with and without neoadjuvant androgen
ablation: Data from CapSure. Int J Radiat Oncol Biol Phys 2004;
60(4):1066–1075.
Steineck G et al: Quality of life after radical prostatectomy or watch-
ful waiting. N Engl J Med 2002;347(11):790–796.
Wei JT et al: Comprehensive comparison of health-related quality of
life after contemporary therapies for localized prostate cancer.
J Clin Oncol 2002;20:557–566.
Wu AK et al: Health related quality of life in patients treated with
multimodal therapy for prostate cancer. J Urol 2008;180:2415.
Relapse and Androgen Deprivation
Chaudhary UB et al: Secondary hormonal manipulations in the
management of advanced prostate cancer. Can J Urol 2005;12(3):
2666–2676.
Chen CD et al: Molecular determinants of resistance to antiandrogen
therapy. Nat Med 2004;10(1):33–39.
Cookson MS : Variation in the definition of biochemical recurrence
in patients treated for localized prostate cancer: The American
Urological Association prostate guidelines for localized prostate
cancer update panel report and recommendations for a standard
in the reporting of surgical outcomes. J Urol 2007; 177:540.
Crawford ED et al: A controlled trial of leuprolide with and without
flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):
419–424.
De La Taille A et al: Intermittent androgen suppression in patients
with prostate cancer. BJU Int 2003;91(1):18–22.
Eisenberger MA et al: Bilateral orchiectomy with or without fluta-
mide for metastatic prostate cancer. N Engl J Med 1998;339(15):
1036–1042.
Freedland SJ et al: Risk of prostate cancer–specific mortality follow-
ing biochemical recurrence after radical prostatectomy. JAMA
2005;294:433–439.
Kumar RJ et al: Preventing and treating the complications of hor-
mone therapy. Curr Urol Rep 2005;6(3):217–223.
Lee AK , D’Amico AV : Utility of prostate-specific antigen kinetics in
addition to clinical factors in the selection of patients for salvage
local therapy. J Clin Oncol 2005;23(32):8192–8197.
Moul JW et al: Early versus delayed hormonal therapy for prostate
specific antigen only recurrence of prostate cancer after radical
prostatectomy. J Urol 2004;171(3):1141–1147.
Nielsen ME et al: Is it possible to compare PSA recurrence-free survival
after surgery and radiotherapy using revised ASTRO Criterion—
“Nadir+2”? Urology 2008;72:389.
Schroder FH et al: Early versus delayed endocrine treatment of pN1–3
M0 prostate cancer without local treatment of the primary tumor:
Results of European Organisation for the Research and Treatment
of Cancer 30846—A phase III study. J Urol 2004; 172(3):923–927.
 NEOPLASMS OF THE PROSTATE GLAND
Studer UE et al: Immediate versus deferred hormonal treatment for
patients with prostate cancer who are not suitable for curative
local treatment: Results of the randomized trial SAKK 08/88.
J Clin Oncol 2004;22(20):4109–4118.
Secondary Therapy and Chemotherapy
Beltran H et al: New therapies for castration-resistant prostate can-
cer: Efficacy and safety. Eur Urol 2011;60(2):279–290.
D’Amico AV et al: Surrogate end point for prostate cancer specific
mortality in patients with nonmetastatic hormone refractory
prostate cancer. J Urol 2005;173(5):1572–1576.
De Bono JS et al: Abiraterone and increased survival in metastatic
prostate cancer. N Engl J Med 2011;364(21):1995–2005.
CHAPTER 23
379
Fizazi K et al: Denosumab versus zoledronic acid for treatment of
bone metastases in men with castration-resistant prostate cancer:
A randomised, double-blind study. Lancet 2011;377:813.
Goodin S et al: Effect of docetaxel in patients with hormone-dependent
prostate-specific antigen progression after local therapy for prostate
cancer. J Clin Oncol 2005;23(15):3352–3357.
Kantoff PW et al: Sipuleucel-T immunotherapy for castration-resistant
prostate cancer. N Engl J Med 2010:363:411.
Rozhansky F et al: Prostate-specific antigen velocity and survival for
patients with hormone-refractory metastatic prostate carcinoma.
Cancer 2005;106(1):63–67.
Tannock IF et al: Docetaxel plus prednisone or mitoxantrone plus pred-
nisone for advanced prostate cancer. N Engl J Med 2004; 351(15):
1502–1512.